See more : ZOOZ Power Limited (ZOOZ) Income Statement Analysis – Financial Results
Complete financial analysis of Medexus Pharmaceuticals Inc. (MEDXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medexus Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- China Merchants Shekou Industrial Zone Holdings Co., Ltd. (001979.SZ) Income Statement Analysis – Financial Results
- SCP & CO Healthcare Acquisition Company (SHACW) Income Statement Analysis – Financial Results
- REC Silicon ASA (0FS8.L) Income Statement Analysis – Financial Results
- Artis Real Estate Investment Trust (ARESF) Income Statement Analysis – Financial Results
- BQE Water Inc. (BTQNF) Income Statement Analysis – Financial Results
Medexus Pharmaceuticals Inc. (MEDXF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medexus.com
About Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M | 25.36M | 7.75M | 4.65M | 2.89M | 3.69M | 3.07M | 0.00 | 0.00 |
Cost of Revenue | 53.54M | 48.06M | 38.77M | 37.66M | 22.99M | 10.38M | 3.85M | 2.08M | 998.43K | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M | 14.98M | 3.90M | 2.57M | 1.89M | 3.69M | 3.07M | 0.00 | 0.00 |
Gross Profit Ratio | 52.64% | 55.54% | 49.45% | 52.73% | 56.15% | 59.08% | 50.37% | 55.24% | 65.44% | 100.00% | 100.00% | 0.00% | 0.00% |
Research & Development | 8.04M | 2.94M | 5.87M | 4.60M | 1.10M | 0.00 | 0.00 | 0.00 | 0.00 | 542.62K | 1.38M | 0.00 | 0.00 |
General & Administrative | 27.86M | 36.86M | 34.52M | 19.28M | 11.77M | 5.64M | 1.58M | 2.15M | 2.72M | 1.21M | 2.02M | 149.56K | 136.14 |
Selling & Marketing | 10.58M | 11.39M | 9.51M | 16.89M | 17.16M | 9.97M | 4.51M | 2.95M | 2.48M | 3.15M | 4.70M | 0.00 | 0.00 |
SG&A | 38.44M | 48.25M | 44.03M | 36.17M | 28.93M | 15.62M | 6.09M | 5.10M | 5.20M | 4.36M | 6.72M | 149.56K | 136.14 |
Other Expenses | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 48.72M | 51.55M | 50.30M | 41.27M | 30.48M | 15.66M | 6.10M | 5.12M | 5.28M | 4.90M | 8.10M | 149.56K | 136.14 |
Cost & Expenses | 102.26M | 99.61M | 89.08M | 78.93M | 53.47M | 26.04M | 9.95M | 7.20M | 6.28M | 4.90M | 8.10M | 149.56K | 136.14 |
Interest Income | 0.00 | 0.00 | 0.00 | 3.00K | 205.89K | 161.72K | 30.82K | 29.96K | 31.95K | 23.21K | 49.23K | 0.00 | 0.00 |
Interest Expense | 13.36M | 13.61M | 12.22M | 9.82M | 6.44M | 2.90M | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 5.81M | 8.05M | 7.71M | 7.90M | 5.26M | 2.38M | 231.16K | 51.87K | 113.48K | 88.12K | 0.00 | 0.00 | 0.00 |
EBITDA | 19.28M | 14.65M | 15.16M | -23.61M | 7.04M | 159.00K | -2.06M | -697.72K | -1.15M | -3.85M | -4.88M | -2.02M | -136.14 |
EBITDA Ratio | 17.05% | 13.48% | -8.12% | 8.43% | 3.25% | 5.58% | -25.62% | -59.93% | -113.69% | -31.76% | -159.09% | 0.00% | 0.00% |
Operating Income | 10.79M | 7.61M | -15.00M | -1.38M | -5.41M | -4.39M | -2.18M | -592.05K | -1.03M | -1.21M | -4.88M | -149.56K | -136.14 |
Operating Income Ratio | 9.55% | 7.04% | -19.55% | -1.73% | -10.32% | -17.32% | -28.09% | -12.72% | -35.72% | -32.78% | -159.09% | 0.00% | 0.00% |
Total Other Income/Expenses | -10.69M | -12.66M | 11.18M | -30.13M | 244.00K | -477.99K | -501.00K | -584.12K | -431.64K | 38.83K | -117.08K | 0.00 | 0.00 |
Income Before Tax | 106.00K | -5.04M | -3.82M | -31.50M | -5.19M | -4.72M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
Income Before Tax Ratio | 0.09% | -4.66% | -4.98% | -39.54% | -9.89% | -18.60% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
Income Tax Expense | 320.00K | -6.26M | -941.00K | -3.24M | -790.44K | 166.29K | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
Net Income | -214.00K | 1.22M | -2.88M | -28.26M | -4.40M | -4.88M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
Net Income Ratio | -0.19% | 1.13% | -3.75% | -35.48% | -8.39% | -19.26% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
EPS | -0.01 | 0.06 | -0.15 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
EPS Diluted | -0.01 | 0.06 | -0.14 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
Weighted Avg Shares Out | 22.32M | 19.98M | 19.45M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Weighted Avg Shares Out (Dil) | 22.32M | 20.52M | 19.86M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Medexus Schedules Second Quarter Fiscal 2022 Conference Call
Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada
Medexus Holds Annual and Special Meeting of Shareholders and Announces Election of Board of Directors
Medexus Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Medexus: Commercial And Late-Stage Rare Disease Pharmaceuticals
Medexus Pharmaceuticals' (MEDXF) CEO Ken d'Entremont on Q1 2022 Results - Earnings Call Transcript
Medexus Pharmaceuticals Reports Financial and Operational Results for First Quarter Fiscal 2022
Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients
Medexus Schedules First Quarter Fiscal 2022 Conference Call
Medexus to Present at Canaccord Genuity's 41st Annual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports